seladelpar inntooltip international nonproprietary name usantooltip united states adopted name developmental code names pparÎ´ receptor agonist investigated drug use according press release examining potential use treatment dyslipidemia metabolic syndrome type diabetes nonalcoholic steatohepatitis nash compound licensed janssen pharmaceutica drug completed phase ii trial primary biliary cholangitis seladelpar demonstrated robust dosedependent clinically significant durable improvements biochemical markers cholestasis inflammation patients pbc risk disease progression seladelpar appeared safe well tolerated associated increase phase iii trial patients pbc also found reduced pruritus improved liver biochemistry despite terminated drug article relating gastrointestinal system stub help wikipedia expanding httpsenwikipediaorgwikiseladelpar